Cargando…
Anti-CD20 therapies and pregnancy in neuroimmunologic disorders: A cohort study from Germany
OBJECTIVE: To report pregnancy outcomes and disease activity (DA) in women with MS, neuromyelitis optica spectrum disorders (NMOSDs), and other neuroimmunologic diseases (ONID) after treatment with rituximab (RTX)/ocrelizumab (OCR) 12 months before or during pregnancy. METHODS: Data were collected i...
Autores principales: | Kümpfel, Tania, Thiel, Sandra, Meinl, Ingrid, Ciplea, Andrea I., Bayas, Antonios, Hoffmann, Frank, Hofstadt-van Oy, Ulrich, Hoshi, Muna, Kluge, Jakob, Ringelstein, Marius, Aktas, Orhan, Stoppe, Muriel, Walter, Annette, Weber, Martin S., Ayzenberg, Ilya, Hellwig, Kerstin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7757754/ https://www.ncbi.nlm.nih.gov/pubmed/33334856 http://dx.doi.org/10.1212/NXI.0000000000000913 |
Ejemplares similares
-
COVID-19 and management of neuroimmunological disorders
por: Hartung, Hans-Peter, et al.
Publicado: (2020) -
Neurological manifestations in autoinflammatory syndromes: a series of 131 patients from our neuroimmunology departement
por: Schuh, E, et al.
Publicado: (2015) -
Very late-onset neuromyelitis optica spectrum disorder beyond the age of 75
por: Krumbholz, Markus, et al.
Publicado: (2015) -
Inpatient care of neuromyelitis optica spectrum disorder in Germany: Nationwide analysis from 2010 to 2021
por: Richter, Daniel, et al.
Publicado: (2023) -
Monoclonal antibody treatment during pregnancy and/or lactation in women with MS or neuromyelitis optica spectrum disorder
por: Ciplea, Andrea Ines, et al.
Publicado: (2020)